Bryn Pharma Appoints Pharmaceutical Industry Veteran Anne Clem Whitaker to Its Board of Directors
RALEIGH, N.C.--(BUSINESS WIRE)--#allergy--Bryn Pharma, LLC (“Bryn” or the “Company”), a privately held pharmaceutical company dedicated to finding a better way for patients and caregivers to treat anaphylaxis, today announced the appointment of Anne Clem Whitaker to its Board of Directors, effective immediately.
Ms. Whitaker brings more than 30 years of extensive leadership and commercialization experience in pharmaceuticals, consumer products and medical devices to Bryn’s board. She has held senior-level executive leadership roles at Sanofi, GlaxoSmithKline, Bausch Health, and multiple CEO roles for private and public development stage companies. Most recently, Ms. Whitaker served as CEO of Aerami Therapeutics before taking on the Chair of the Board position in November 2020.
“Anne is an accomplished pharmaceutical executive who brings strong cross-functional operational and commercialization expertise to Bryn. She has a demonstrated track record of building successful businesses and leading teams through transformational change to drive business growth. We look forward to her contributions as we work toward the goal of bringing our innovative anaphylaxis treatment to market,” said David Dworaczyk, PhD, CEO. “Anne’s fresh perspectives, combined with the experience of our board and senior management team, will help usher in a new day for people facing the dire consequences of severe allergic reactions. We are thrilled that she is joining our team.”
“Bryn has made tremendous strides in researching and developing a new approach to treating life-threatening allergic reactions. I’m excited to collaborate with the company’s leadership to chart a course in bringing their investigational technology to market,” said Ms. Whitaker.
Ms. Whitaker currently serves as a healthcare-focused advisor for private equity firms and as an independent director on the board of three public companies including Faron Pharmaceuticals (FARN:LSE), Caladrius (CLBS:NASDAQ), and Mallinckrodt. She also serves on the board of Curio Digital Therapeutics, Inc., a privately held women’s health focused digital therapeutics company and the Board of Trustees for the University of North Alabama. Prior to joining Aerami, Ms. Whitaker served in multiple C-suite roles for emerging biotechnology and specialty pharmaceutical companies. Prior to these roles, Ms. Whitaker served as the North America Pharmaceutical Region Head and President for Sanofi from 2011 to 2014, and as Senior Vice President from 2008 to 2011 at GlaxoSmithKline, where she ran their Cardiovascular, Metabolic and Urology business in the US. From 1992 to 2008, Ms. Whitaker held several commercial roles at GSK and a senior level global role as the Senior Vice President, Head of the Organizational and Leadership Development Center of Excellence based in London. Ms. Whitaker started her career in the pharmaceutical industry as a pharmaceutical sales representative for the Upjohn Company after receiving her Bachelor of Science from the University of North Alabama.
About Bryn Pharma
Bryn Pharma is a privately held pharmaceutical company founded by patients for patients. Bryn is focused on positively disrupting the existing market for epinephrine autoinjectors by delivering an accessible, easy-to-use alternative that better meets the needs of patients. Bryn Pharma seeks to provide this growing population at risk for anaphylaxis with A Better Way to be prepared for a life-threatening allergic reaction. For more information visit www.brynpharma.com.
Forward Looking Statements
Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits are forward-looking statements. A number of risks and uncertainties, such as risks related to product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the Company’s products to patients, market and physician acceptance of the Company’s products, intellectual property protection and competitive product offerings, could cause actual events to differ from the expectations indicated in these forward-looking statements. You are cautioned not to put any undue reliance on any forward-looking statement. This press release is neither an offer to sell nor a solicitation of an offer to purchase any particular securities. Any such offer or solicitation will be made only pursuant to definitive legal agreements prepared specifically for such purpose. An investment in the Company’s securities entails significant risks and is suitable only for sophisticated investors who can afford a loss of their entire investment; no assurance can be given that investment objectives will be achieved. In considering the performance information contained herein, you should bear in mind that past performance is not necessarily indicative of future results; there can be no assurance that the Company will achieve comparable results or that any projected returns will be met. The Company does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Rebecca Novak Tibbitt
Rebecca [at] RNTCommunications.com